Abstract 102P
Background
In view of a higher likelihood of risk of having advanced adenoma or invasive cancer in the individual with above average, we investigated whether receiving subsequent faecal immunochemical tests (FITs) in the intervals between colonoscopies could reduce the risk of colorectal cancer (CRC) and advanced colorectal neoplasia (ACN) incidence.
Methods
A retrospective cohort study was performed among high-risk population for CRC between January 2012 and December 2022, in Tianjin, China. The incidence of CRC and ACN were calculated for the FIT surveillance and non-FIT surveillance groups and reported as the number of events per 100000 person-years. Cox proportional hazards model models were applied to evaluate the risks of CRC and ACN, with crude and adjusted hazard ratios (HRs) and 95% confidence intervals (CI).
Results
We included 12515 participants with a high risk of CRC, aged 40-74 years, of whom 4980 received subsequent FIT between colonoscopies during the study period. Among these participants, 51 CRC cases occurred in the non-FIT surveillance group (incidence rate, 233.88 per 100000 person-years) and there were 29 cases of CRC in the FIT surveillance group (incidence rate, 184.85 per 100000 person-years). The cumulative events of the advanced adenoma group were highest, followed by the non-advanced adenoma group, then the no neoplasia group stratified based on the prior colonoscopy findings. Compared with the non-FIT surveillance group, the FIT surveillance group had a 54% decreased risk of developing CRC (HR, 0.46; 95% CI, 0.29-0.74) and a 45% decreased risk of developing ACN (HR, 0.55; 95% CI, 0.47-0.64).
Conclusions
In this CRC surveillance program, our study found that high-risk participants who received subsequent FIT surveillance in the intervals between colonoscopy were associated with a reduction of CRC and ACN incidence, which indicated the value and utility of FIT in the surveillance program.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This work was supported by the National Natural Science Foundation of China (Grant. No: 81973135 and 81972826) and Science and Technology Commission of Shanghai Municipality (Grant. No: 21XD1402600).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
218P - Clinical effectiveness of tislelizumab combined with gemcitabine/cisplatin (GC) versus GC as adjuvant therapy in high-risk muscle-invasive urothelial carcinoma (MIUC): A real-world study
Presenter: xingliang Tan
Session: Poster Display
Resources:
Abstract
219P - Clinical effectiveness of tislelizumab plus TKI as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): A real-world study
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
220P - Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma
Presenter: Wenhao Xu
Session: Poster Display
Resources:
Abstract
221P - Genetic polymorphism of genes encoding cytokines interleukin1 1-alpha and TNF-alpha in non-muscle invasive bladder cancer
Presenter: Anil Kumar
Session: Poster Display
Resources:
Abstract
222P - The association between response to enfortumab vedotin and peripheral neuropathy: A multicenter retrospective study in Japan
Presenter: Nozomi Hayakawa
Session: Poster Display
Resources:
Abstract
223P - Patient and healthcare practitioner preferences for treatments in advanced renal cell carcinoma
Presenter: Niara Oliveira
Session: Poster Display
Resources:
Abstract
224P - WUTSUP-01: Phase II trial of neoadjuvant toripalimab and chemotherapy in locally advanced upper tract urothelial carcinoma
Presenter: Yige Bao
Session: Poster Display
Resources:
Abstract
225P - A novel multianalyte signature for stratifying Indian non-muscle invasive bladder cancer: A single center observational study
Presenter: Hari P S
Session: Poster Display
Resources:
Abstract
226P - Prognosis stratification of immunotherapy by a mutational signature in urothelial carcinoma
Presenter: Xuebing Han
Session: Poster Display
Resources:
Abstract
227P - Proteomic analysis of urothelial lesions reveals novel diagnostic biomarkers to distinguish pathologic pitfalls and protein-protein interactions
Presenter: Changlim Hyun
Session: Poster Display
Resources:
Abstract